Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases

Table 6 Highlights of chemoembolization literature for colorectal liver metastases

Ref.	Level of evidence	Year	Study details	Response rate (SD, CR, PR)	PFS/TTP (mo)	1 yr OS	2 yr OS	Median OS (mo)
Lang and Brown[126]	II-2	1993	TACE, Doxorubicin	63		65%	22%
			Prospective cohort, 46 patients
Hong et al[127]	II-2	2009	TACE, cisplatin + doxorubicin + mitomycin C			43%	10%	7.7
			Retrospective cohort, 21 patients
Vogl et al[82]	II-2	2009	TACE, mitomycin C alone or with gemcitabine vs irinotecan	63		62%	28%	14
			Prospective cohort, 463 patients
Albert et al[77]	II-2	2011	TACE, cisplatin, doxorubicin, mitomycin C	43	3	36%	13%	9
			Retrospective cohort, 121 patients
Martin et al[128]	II-2	2011	DEB-TACE (DEBIRI)			75%		19
			Prospective cohort, 55 patients
Fiorentini et al[79]	I	2012	DEB-TACE (DEBIRI)	80	7		56%	15
			Randomized Controlled Trial, 74 patients, DEBIRI vs FOLFIRI
Narayanan et al[129]	II-2	2013	DEB-TACE (DEBIRI)	68.6	3			13.3
			Retrospective cohort, 28 patients
Iezzi et al[83]	II-1	2015	DEB-TACE (DEBIRI) + Capecitabine	60	4			7.3
			Prospective Phase II Trial, 20 patients

OS: Overall survival; TACE: Transcatheter arterial chemoembolization; TTP: Time to progression.